Analysts Issue Forecasts for IceCure Medical FY2027 Earnings

IceCure Medical Ltd (NASDAQ:ICCM) – Research analysts at Brookline Capital Management dropped their FY2027 earnings estimates for IceCure Medical in a research report issued on Tuesday, November 26th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings per share of $0.23 for the year, down from their previous estimate of $0.25. The consensus estimate for IceCure Medical’s current full-year earnings is ($0.27) per share. Brookline Capital Management also issued estimates for IceCure Medical’s FY2028 earnings at $0.33 EPS.

Other research analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $2.50 price objective on shares of IceCure Medical in a research report on Wednesday. Alliance Global Partners upgraded IceCure Medical to a “strong-buy” rating in a research report on Friday, November 1st.

IceCure Medical Price Performance

NASDAQ:ICCM opened at $0.83 on Thursday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.97 and a quick ratio of 2.54. The stock has a market cap of $37.96 million, a P/E ratio of -2.77 and a beta of 0.48. The company has a fifty day moving average price of $0.65 and a 200 day moving average price of $0.73. IceCure Medical has a one year low of $0.48 and a one year high of $1.57.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in IceCure Medical stock. Renaissance Technologies LLC bought a new position in shares of IceCure Medical Ltd (NASDAQ:ICCM) in the second quarter, according to the company in its most recent filing with the SEC. The firm bought 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned approximately 0.15% of IceCure Medical as of its most recent SEC filing. Hedge funds and other institutional investors own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.